Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicaid Rebate Liability Is With Manufacturers, Not PBMs - Express Scripts

Executive Summary

Manufacturers, not PBMs, are liable for accurate reporting of "best price" rebates, Express Scripts General Counsel Thomas Boudreau observed during an investor conference call March 8.

You may also be interested in...



Lilly Zyprexa Marketing Info Sought By Philadelphia U.S. Attorney

Lilly's antipsychotic Zyprexa is among the drugs targeted in the Philadelphia U.S. Attorney's ongoing probe into prescription drug marketing practices

Lilly Zyprexa Marketing Info Sought By Philadelphia U.S. Attorney

Lilly's antipsychotic Zyprexa is among the drugs targeted in the Philadelphia U.S. Attorney's ongoing probe into prescription drug marketing practices

Abbott “Nominal Prices” Cited In Medco Suit; “Improper” Payments Alleged

Medco's access to "nominally priced" Abbott medicines is one example cited by the Philadelphia U.S. Attorney of an "inducement" accepted by the pharmacy benefit management company

Related Content

UsernamePublicRestriction

Register

PS035732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel